European Union signed a contract for 55 thousand. doses of a potential new drug for COVID-19, developed by the American manufacturer Regeneron and the Swiss pharmaceutical company Roche. This is the first EU contract for this type of drug.
–
The EU already reached an agreement with Roche in April, but only now has these arrangements been made known. Member States will be able to purchase Roche-Regeneron once it has been approved by European Medicines Agency (EMA) or national regulatory authorities.
–
EMA said it has not set a date for the possible approval of this preparation as companies must first formally apply for a conditional authorization.
–
EMA said it had not set a date for possible approval of the medicine as an application for conditional authorization must first be submitted.
–
